Afinitor Adds Breast Cancer Indication On Strength Of Progression-Free Survival Benefit

Lack of crossover in Novartis’ pivotal BOLERO-2 trial could lead to a clean picture of the mTOR inhibitor’s ability to prolong survival, the ultimate gold standard in cancer drug approvals. An interim analysis showed a survival advantage that fell short of reaching statistical significance.